Everybody’s talking about CAR-T for autoimmune disease. Allogene, Kyverna, CRISPR Therapeutics. The data keeps coming and it keeps looking good. B-cell depletion via engineered T cells is becoming a real therapeutic category.
But Mesoblast is asking a different question. What if you put the CAR on a mesenchymal stromal cell instead?
The company acquired an exclusive global license to a chimeric antigen receptor platform developed at Mayo Clinic, and plans to engineer CAR constructs into its existing MSC therapy platform. The resulting CAR-MSC products would combine the immunomodulatory properties of MSCs with the targeting precision of CAR technology.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The logic is interesting. MSCs are natural immunomodulators. They don’t kill. They calm. They suppress inflammation, promote tissue repair, and home to sites of damage. Mesoblast already has the only FDA-approved MSC product, Ryoncil, for pediatric steroid-refractory graft-versus-host disease. And they recently got FDA clearance to jump straight to a registrational trial of Ryoncil in Duchenne muscular dystrophy.
By adding CAR constructs, Mesoblast aims to give MSCs tissue-specific homing. One early strategy involves engineering CD19-expressing CAR-MSCs that can modulate B cell-driven pathology in autoimmune conditions like lupus nephritis, ulcerative colitis, and Crohn’s disease.
This is a fundamentally different approach than CAR-T for autoimmune disease. CAR-T kills B cells. CAR-MSC would modulate them. The question is whether modulation delivers the same depth of response that depletion does, and whether the safety profile is meaningfully better.
Mesoblast has the manufacturing infrastructure (they’ve scaled allogeneic MSC production to industrial levels), over 1,000 granted patents, and a proven regulatory track record. If anyone can make CAR-MSC work, they have the platform to do it. But this is early. No clinical trials announced, no timelines disclosed. The bet is on the biology, and the biology is unproven.
Still, in a world where the autoimmune CAR-T space is getting crowded fast, a differentiated modality with a different mechanism is worth watching. Even if it’s the quieter cousin at the table.
